RxDoctor Payments Data

Lawrence Golbe

Neurology · New Brunswick, NJNPI 1215002795

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $19,070 of the $20,279 with a category attached, or 94.0%. 6 manufacturers reported payments, led by Biogen at 59.3% of the total. Reporting peaked in 2019 at $12,022 and has fallen 94.2% since, to $700 in 2023.

$20,279in general payments, 2019–2025

Across 19 payments — averaging $1067.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$12K
  • UCB SA$6K
  • Roche Products Limited$1K
  • Orphai Therapeutics Inc.$700
  • Mitsubishi Tanabe Pharma Holdings America, Inc.$688
  • Genentech USA, Inc.$44
$428,424in research payments, 2019–2025

Across 24 payments — averaging $17,851 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$259K
  • Biogen$169K

What the payments were for

  • Consulting fees$19,07094%
  • Travel & lodging$7954%
  • Food & beverage$4152%

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$20,279 in reported general payments places this provider in the 80th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Other neurology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →